
						
							
						
						
							<!--
							google_ad_client = "pub-5806585833518451";
							/* 300x250, created 6/2/09 - iposol_ipo_detail_top */
							google_ad_slot = "4379562531";
							google_ad_width = 300;
							google_ad_height = 250;
									-->
							
							
							
						

						Incorporated in 1973, Alkem Labs is leading India based pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.Alkem Labs produces branded generics, generic drugs, active pharmaceutical ingredients and neutraceuticals, which they market in India and 55 countries internationally, primarily the United States.Company's pharmaceutical business is organized into domestic and international operations. Alkem Labs has a portfolio of over 736 brands in India. Company's most significant therapeutic areas in domestic market are anti-infectives, gastro-intestinal, pain and analgesics, and vitamins, minerals and nutrients.Alkem Labs have a total of 16 manufacturing facilities: 14 manufacturing facilities at five locations in India and two in the United States. Company have four research and development facilities, two in India and two in the United States. As of June 30, 2015, company employed 483 scientists in research and development functions.Highlights:1. Alkem Labs is 5th largest pharmaceutical company in India in terms of domestic sales. 2. Alkem Labs products are also sold in 56 countries. In the United States, company has filed 66 abbreviated new drug applications. 3. Company sells a range of high-quality, cost effective generic drugs to major drug chains, pharmaceutical retailers, wholesalers, food and grocery stores, distributors and managed care companies in the United States.

						
						
							
						
						

						Company Promoters:Alkem Labs has 23 Promoters who jointly hold 64,302,440 Equity Shares of the Company which, in aggregate, constitutes 53.8% of the issued and paid-up Equity Share capital of our Company.

						Company Financials:
	ParticularsFor the year/period ended (in Rs. Million)
	31 Mar 1531 Mar 1431 Mar 1331 Mar 12
	Total Income33,595.2028,395.8024,690.1020,640.10
	Profit After Tax (PAT)4,370.904,402.004,667.804,318.10


						
							<!--
								google_ad_client = "pub-5806585833518451";
								/* 300x250, created 9/3/09 - IPO Detail Center */
								google_ad_slot = "7910498455";
								google_ad_width = 300;
								google_ad_height = 250;
								-->
							
							
							
						

						Objects of the Issue:The objects of the Offer are:1. To achieve the benefits of listing the Equity Shares on the Stock Exchanges and 2. For the sale of 12,853,442 Equity Shares by the Selling Shareholders.

						Issue Detail:
						  »»  Issue Open: Dec 8, 2015 - Dec 10, 2015
							  »»  Issue Type: Book Built Issue IPO
							  »»  Issue Size: 12,853,442 Equity Shares of Rs 2 aggregating up to Rs 1,349.61 Cr
							
							
							  »»  Face Value: Rs 2 Per Equity Share
							  »»  Issue Price: Rs. 1020 - Rs. 1050 Per Equity Share
							  »»  Market Lot: 14 Shares
							  »»  Minimum Order Quantity: 14 Shares
							  »»  Listing At: BSE, NSE
						

						


						
						Alkem Laboratories IPO Reviews:
						
							
							Alkem Laboratories Limited IPO review by Dilip Davda
							
						
						


						
							
						

						
							Issue Subscription Detail / Current Bidding StatusNumber of Times Issue is Subscribed (BSE + NSE)As on Date & TimeQIBNIIRIIEmployeeTotalShares Offered / Reserved2,510,9061,883,1794,394,086298,9139,087,084Day 1 - Dec 8, 2015 17:00 IST0.41000.09000.44000.14000.3500Day 2 - Dec 9, 2015 17:00 IST2.33000.64001.28000.42001.4100Day 3 - Dec 10, 2015 23:15 IST57.1900129.96003.17000.670044.2900
						
					
